GlassScriptPhysician profile
Ashish Kapoor
NPI 1164733739
$328,662.40
in general payments reported to CMS, 2019-2025
67 companies · $69K in 2025
The $69K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $66K · 2021: $46K · 2022: $41K · 2023: $27K · 2024: $60K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Honoraria: $33K · Food and Beverage: $17K · Travel and Lodging: $7,577 · Consulting Fee: $1,525 · Education: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,963.00 |
| Honoraria | $32,500.00 |
| Food and Beverage | $17,033.91 |
| Travel and Lodging | $7,576.83 |
| Consulting Fee | $1,525.00 |
| Education | $1,447.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $107,569.96 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $63,502.52 | 2021-2025 | |
| Tg Therapeutics, INC. | $55,390.36 | 2022-2025 | |
| Axsome Therapeutics, INC. | $29,431.72 | 2025 | Symbravo |
| Allergan, INC. | $27,783.75 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $10,643.75 | 2019-2025 | Ongentys, Ingrezza |
| Amneal Pharmaceuticals LLC | $7,104.37 | 2019-2025 | Ongentys, Ongentys 50mg Capsules 30, Crexont |
| Biohaven Pharmaceutical Holding Company LTD. | $5,782.11 | 2022 | |
| Pfizer INC. | $5,742.72 | 2022-2025 | |
| Medtronic, INC. | $1,783.57 | 2021-2025 | Visualase, Corevalve Evolut R |
| Lundbeck LLC | $1,506.51 | 2020-2025 | Vyepti, Rexulti |
| Biogen, INC. | $1,232.30 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Celgene Corporation | $1,170.29 | 2020-2025 | Zeposia |
| Monteris Medical Corporation | $870.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $717.08 | 2019-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $669.02 | 2020-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $662.02 | 2020-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $611.06 | 2020-2025 | Xcopri |
| Biohaven Pharmaceuticals, INC. | $590.65 | 2020-2021 | |
| Amgen INC. | $580.81 | 2019-2025 | Uplizna |
| Baxter Healthcare | $406.31 | 2023-2024 | Actifuse |
| Abbott Laboratories | $400.25 | 2019-2024 | Infinity |
| Globus Medical, INC. | $374.05 | 2025 | Senza |
| Lilly USA, LLC | $372.64 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Boston Scientific Corporation | $367.46 | 2021-2025 | General - Dbs, Wavewriter Alpha Prime 16 |
| Ani Pharmaceuticals, INC. | $363.15 | 2023-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $306.22 | 2019-2025 | Briviact, Nayzilam |
| Impel Pharmaceuticals INC. | $278.09 | 2022-2023 | Trudhesa |
| Stryker Corporation | $241.03 | 2021 | |
| Medtronic Vascular, INC. | $237.63 | 2019 | |
| Grifols USA, LLC | $207.05 | 2022-2025 | Gamunex-C |
| Eisai INC. | $164.85 | 2019-2024 | |
| Neurelis, INC. | $159.67 | 2021-2024 | Valtoco |
| Philips North America LLC | $138.42 | 2022 | |
| Incyte Corporation | $131.47 | 2019 | |
| Acorda Therapeutics, INC | $125.00 | 2019 | |
| Scilex Pharmaceuticals INC. | $112.31 | 2021-2025 | Ztlido |
| Mdd US Operations, LLC | $100.58 | 2020-2025 | Apokyn, Apokyn |
| Genentech USA, INC. | $97.41 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $90.53 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $68.01 | 2024-2025 | Vyvgart Hytrulo |
| Ge Healthcare | $51.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $44.19 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $40.40 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $38.34 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $32.56 | 2025 | Ponvory |
| Mallinckrodt Hospital Products INC. | $31.03 | 2024 | Acthar |
| Aucta Pharmaceuticals, INC. | $30.67 | 2024 | Motpoly Xr |
| Merck Sharp & Dohme LLC | $28.96 | 2021 | |
| Arbor Pharmaceuticals, INC. | $25.13 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $24.50 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $22.38 | 2019-2021 | |
| Octapharma USA, INC. | $17.17 | 2025 | Panzyga |
| Kedrion Biopharma, INC. | $16.49 | 2025 | Kedrab, Koate, Gammaked |
| Takeda Pharmaceuticals U.S.A., INC. | $16.45 | 2025 | Hyqvia |
| Catalyst Pharmaceuticals, INC. | $16.44 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.16 | 2022 | |
| Mallinckrodt Enterprises LLC | $14.36 | 2019 | |
| Grt US Holding, INC. | $14.26 | 2022 | |
| Acadia Pharmaceuticals INC | $13.91 | 2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $13.80 | 2024 | Nuedexta |
| Vertical Pharmaceuticals, LLC | $13.73 | 2020 | |
| Horizon Therapeutics Plc | $12.00 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $11.24 | 2021 | |
| Genzyme Corporation | $10.89 | 2019 | |
| Impel Pharmaceuticals LLC | $10.36 | 2024 | Trudhesa |
| Travere Therapeutics, INC. | $7.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.